复方苁蓉益智胶囊治疗血管性痴呆临床应用专家共识  

Expert consensus on clinical application of Compound Congrong Yizhi Capsules in treatment of vascular dementia

作　　者：梁晓 金香兰[2] 彭丹涛[3] 郭蓉娟[2] 廖星[4] 张允岭 编制组 LIANG Xiao;JIN Xiang-lan;PENG Dan-tao;GUO Rong-juan;LIAO Xing;ZHANG Yun-ling;editorial team(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;China-Japan Friendship Hospital,Beijing 100029,China;Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;不详)

机构地区：[1]中国中医科学院西苑医院,北京100091 [2]北京中医药大学东方医院,北京100078 [3]中日友好医院,北京100029 [4]中国中医科学院中医临床基础医学研究所,北京100700 [5]不详

出　　处：《中国中药杂志》2022年第23期6514-6519,共6页China Journal of Chinese Materia Medica

基　　金：国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202007);中国中医科学院科技创新工程项目(CI2021A05503);中医药防治脑病传承创新团队项目(CI2021B006);中央级公益性科研院所基本科研业务费专项(ZZ13-024-3)。

摘　　要：复方苁蓉益智胶囊在临床上较为广泛地应用于血管性认知障碍疾病的长期治疗和协同治疗,经多年临床观察,其对血管性认知障碍疾病具有明显疗效,受到多个指南、共识以及丛书的推荐。该共识针对血管性痴呆的治疗而制定,在总结临床医生应用经验的基础上,结合现有循证证据,最终通过名义组法达成了11条推荐意见/共识建议,提出了复方苁蓉益智胶囊治疗血管性痴呆的适应证、用法用量、疗程、用药时间、合并用药和注意事项等,并说明了临床应用的安全性。该共识适用于复方苁蓉益智胶囊治疗血管性痴呆患者,适合全国各级医院的脑病科(神经内科)、老年病科及综合医院中医科等临床医师使用。该共识已通过中华中医药学会的审核,并进行了发布,编号GS/CACM 298-2022。Compound Congrong Yizhi Capsules is widely used in clinic for the long-term treatment and synergistic treatment of vascular cognitive impairment. After years of clinical observation, it has an obvious curative effect on the treatement of vascular cognitive impairment and has been recommended by multiple guidelines, consensuses, and series. This consensus was formulated for the treatment of vascular dementia. On the basis of summarizing the application experience of clinicians, and combined with the existing evidence-based evidence, 11 recommendations/consensus recommendations were finally reached through the nominal group method. The indications, usage and dosage, course of treatment, medication time, concomitant medication, and precautions of Congrong Yizhi Capsules in the treatment of vascular dementia were proposed, and the safety of the clinical application was described. This consensus is applicable to the use of Compound Congrong Yizhi Capsules in the treatment of patients with vascular dementia, and can be used by clinicians from the departments of encephalopathy(neurology), geriatrics, and traditional Chinese medicine in general hospitals. This consensus has been approved by China Association of Chinese Medicine, with the number of GS/CACM 298-2022.

关 键 词：血管性痴呆 专家共识 复方苁蓉益智胶囊 中成药 GRADE 

分 类 号：R277.7[医药卫生—中医学]